Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia 2016; 30: 666–673.

    CAS  Article  Google Scholar 

  2. 2

    Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A et al. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort. Leukemia 2016; 30: 1793–1795.

    CAS  Article  Google Scholar 

  3. 3

    Nazha A, Narkhede M, Przychodzen B, Zarzour A, Carraway HE, Patel B et al. The impact of different TP53 mutations on outcome in patients with myelodysplastic syndromes (MDS). Clin Lymphoma Myeloma Leuk 2015; 15: S45.

    Article  Google Scholar 

  4. 4

    Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD et al. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget 2016; e-pub ahead of print 6 May 2016; doi:10.18632/oncotarget.9200.

  5. 5

    Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013; 160: 660–672.

    CAS  Article  Google Scholar 

  6. 6

    Pellagatti A, Roy S, Genua CD, Burns A, McGraw K, Valletta S et al. Targeted re-sequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Leukemia 2016; 30: 247–250.

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to E Padron.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sallman, D., Komrokji, R., List, A. et al. Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’. Leukemia 31, 767–768 (2017).

Download citation


Quick links